These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 32452705)

  • 1. Initial dosage optimization of tacrolimus in Chinese pediatric patients undergoing kidney transplantation based on population pharmacokinetics and pharmacogenetics.
    Chen X; Wang DD; Xu H; Li ZP
    Expert Rev Clin Pharmacol; 2020 May; 13(5):553-561. PubMed ID: 32452705
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Initial dose optimization of tacrolimus for children with systemic lupus erythematosus based on the CYP3A5 polymorphism and coadministration with Wuzhi capsule.
    Chen X; Wang D; Xu H; Li Z
    J Clin Pharm Ther; 2020 Apr; 45(2):309-317. PubMed ID: 31755126
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population pharmacokinetic analysis and dosing guidelines for tacrolimus co-administration with Wuzhi capsule in Chinese renal transplant recipients.
    Jing Y; Kong Y; Hou X; Liu H; Fu Q; Jiao Z; Peng H; Wei X
    J Clin Pharm Ther; 2021 Aug; 46(4):1117-1128. PubMed ID: 33768546
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Wuzhi capsule and haemoglobin influence tacrolimus elimination in paediatric kidney transplantation patients in a population pharmacokinetics analysis: A retrospective study.
    Wang DD; Chen X; Li ZP
    J Clin Pharm Ther; 2019 Aug; 44(4):611-617. PubMed ID: 30864229
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimization of initial dosing scheme of tacrolimus in pediatric refractory nephrotic syndrome patients based on CYP3A5 genotype and coadministration with wuzhi-capsule.
    Chen X; Wang DD; Xu H; Li ZP
    Xenobiotica; 2020 May; 50(5):606-613. PubMed ID: 31530218
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tacrolimus population pharmacokinetics according to CYP3A5 genotype and clinical factors in Chinese adult kidney transplant recipients.
    Zhang HJ; Li DY; Zhu HJ; Fang Y; Liu TS
    J Clin Pharm Ther; 2017 Aug; 42(4):425-432. PubMed ID: 28401703
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Weight,
    Hu K; Pan JJ; Qu WQ; He SM; Yang Y; Shi HZ; Zhang YJ; Chen X; Wang DD
    Curr Pharm Des; 2024; 30(34):2736-2748. PubMed ID: 39129279
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of drug combination on tacrolimus target dose in renal transplant patients with different
    Zhang SF; Tang BH; Wei AH; Du Y; Guan ZW; Li Y
    Xenobiotica; 2022 Mar; 52(3):312-321. PubMed ID: 35395919
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects and safety evaluation of Wuzhi Capsules combined with tacrolimus for the treatment of kidney transplantation recipients.
    Cheng F; Li Q; Wang J; Zeng F; Zhang Y
    J Clin Pharm Ther; 2021 Dec; 46(6):1636-1649. PubMed ID: 34342024
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population pharmacokinetics and pharmacogenetics of tacrolimus in de novo pediatric kidney transplant recipients.
    Zhao W; Elie V; Roussey G; Brochard K; Niaudet P; Leroy V; Loirat C; Cochat P; Cloarec S; André JL; Garaix F; Bensman A; Fakhoury M; Jacqz-Aigrain E
    Clin Pharmacol Ther; 2009 Dec; 86(6):609-18. PubMed ID: 19865079
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Single-Nucleotide Polymorphism of CYP3A5 Impacts the Exposure to Tacrolimus in Pediatric Renal Transplant Recipients: A Pharmacogenetic Substudy of the TWIST Trial.
    Billing H; Höcker B; Fichtner A; van Damme-Lombaerts R; Friman S; Jaray J; Vondrak K; Sarvary E; Dello Strologo L; Oellerich M; von Ahsen N; Tönshoff B
    Ther Drug Monit; 2017 Feb; 39(1):21-28. PubMed ID: 28030534
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Effect of Weight and CYP3A5 Genotype on the Population Pharmacokinetics of Tacrolimus in Stable Paediatric Renal Transplant Recipients.
    Prytuła AA; Cransberg K; Bouts AH; van Schaik RH; de Jong H; de Wildt SN; Mathôt RA
    Clin Pharmacokinet; 2016 Sep; 55(9):1129-43. PubMed ID: 27138785
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dosing strategy of tacrolimus when co-administered with
    Dai R; Cai Y; Li J; Liu X; Fu Q; Huang M; Wang C; Chen P
    Int J Clin Pharmacol Ther; 2024 Nov; 62(11):507-516. PubMed ID: 39157918
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tacrolimus pharmacokinetics and pharmacogenetics: influence of adenosine triphosphate-binding cassette B1 (ABCB1) and cytochrome (CYP) 3A polymorphisms.
    Op den Buijsch RA; Christiaans MH; Stolk LM; de Vries JE; Cheung CY; Undre NA; van Hooff JP; van Dieijen-Visser MP; Bekers O
    Fundam Clin Pharmacol; 2007 Aug; 21(4):427-35. PubMed ID: 17635182
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of tacrolimus dosage in the early period after heart transplantation: a population pharmacokinetic approach.
    Han Y; Zhou H; Cai J; Huang J; Zhang J; Shi SJ; Liu YN; Zhang Y
    Pharmacogenomics; 2019 Jan; 20(1):21-35. PubMed ID: 30730287
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lack of tacrolimus circadian pharmacokinetics and CYP3A5 pharmacogenetics in the early and maintenance stages in Japanese renal transplant recipients.
    Satoh S; Kagaya H; Saito M; Inoue T; Miura M; Inoue K; Numakura K; Tsuchiya N; Tada H; Suzuki T; Habuchi T
    Br J Clin Pharmacol; 2008 Aug; 66(2):207-14. PubMed ID: 18429967
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population pharmacokinetics and pharmacogenetics of once daily prolonged-release formulation of tacrolimus in pediatric and adolescent kidney transplant recipients.
    Zhao W; Fakhoury M; Baudouin V; Storme T; Maisin A; Deschênes G; Jacqz-Aigrain E
    Eur J Clin Pharmacol; 2013 Feb; 69(2):189-95. PubMed ID: 22706623
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of CYP3A4 and CYP3A5 polymorphisms on tacrolimus pharmacokinetics in Chinese adult renal transplant recipients: a population pharmacokinetic analysis.
    Zuo XC; Ng CM; Barrett JS; Luo AJ; Zhang BK; Deng CH; Xi LY; Cheng K; Ming YZ; Yang GP; Pei Q; Zhu LJ; Yuan H; Liao HQ; Ding JJ; Wu D; Zhou YN; Jing NN; Huang ZJ
    Pharmacogenet Genomics; 2013 May; 23(5):251-61. PubMed ID: 23459029
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CYP3A5 polymorphisms and their effects on tacrolimus exposure in an ethnically diverse South African renal transplant population.
    Muller WK; Dandara C; Manning K; Mhandire D; Ensor J; Barday Z; Freercks R
    S Afr Med J; 2020 Jan; 110(2):159-166. PubMed ID: 32657689
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Tacrolimus on the pharmacokinetics of bioactive lignans of Wuzhi tablet (Schisandra sphenanthera extract) and the potential roles of CYP3A and P-gp.
    Qin XL; Chen X; Zhong GP; Fan XM; Wang Y; Xue XP; Wang Y; Huang M; Bi HC
    Phytomedicine; 2014 Apr; 21(5):766-72. PubMed ID: 24462213
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.